|
Editors
Anne S. De Groot, M.D.
Director, TB/HIV Research Lab, Brown Medical School
Frederick L. Altice, M.D.
Director, HIV in Prisons Program, Yale University AIDS Program
Joseph Bick, M.D.
Director, HIV Treatment Services, California Medical Facility, California Department of Corrections
Senior Advisors
Theodore M. Hammett, Ph.D.
Abt Associates
AdvertisementNed E. Heltzer, R.Ph., M.S.
Heltzer Associates
Ralf Jürgens
Canadian AIDS Law Legal Network
David P. Paar, M.D.
University of Texas Medical Branch
Joseph Paris, Ph.D., M.D.
CCHP Georgia Dept. of Corrections
David Thomas, J.D., M.D.
Florida Dept. of Corrections
Lester Wright, M.D.
New York State Dept. of Corrections
Associate Editors
Dean Rieger, M.D.
Indiana Dept. of Corrections
Josiah Rich, M.D.
Brown University School of Medicine, The Miriam Hospital
Stephen Tabet, M.D., M.P.H.
Univ. of Washington Division of Infectious Disease Seattle HIVNET
David A. Wohl, M.D.
University of North Carolina
Managers
Dennis Thomas
Brown University AIDS Program
Michelle Gaseau
The Corrections Connection
Layout
Kimberly Backlund-Lewis
The Corrections Connection
Distribution
Screened Images Multimedia
Managing Editor
Rebecca Nerenberg
HIV Education Prison Project
The editorial board and contributors to HEPP News include national and regional correctional professionals, selected on the basis of their experience with HIV care in the correctional setting and their familiarity with current HIV treatment. We encourage submissions, feedback, and correspondence from our readership.
Faculty Disclosure
In accordance with the Accreditation Council for Continuing Medical Education Standards for Commercial Support, the faculty for this activity have been asked to complete Conflict of Interest Disclosure forms. Disclosures are listed at the end of articles. All of the individual medications discussed in this newsletter are approved for treatment of HIV and hepatitis unless otherwise indicated. For the treatment of HIV and hepatitis infection, many physicians opt to use combination antiretroviral therapy which is not addressed by the FDA.
HEPP News is grateful for the support of the following companies through unrestricted educational grants:
- Major Support: Agouron Pharmaceuticals and Dupont Pharmaceuticals
- Sustaining: Abbott Laboratories, Boehringer-Ingelheim/Roxane Laboratories, Merck & Co., and Roche Pharmaceuticals
- Supporting: OrthoBiotech
|